Wells Fargo analyst Derek Archila maintained a Buy rating on Oric Pharmaceuticals on October 16 and set a $25.00 price target, compared with the company’s closing share price of $12.35 last Friday. TipRanks identifies Archila as a 5-star analyst with an average return of 16.2% and a 49.58% success rate on recommended stocks; he covers the Healthcare sector and follows companies including Celldex, Incyte, and Argenx Se. Oric has a Strong Buy analyst consensus and a $23.11 average price target, representing 87.13% upside. J.P. Morgan assigned its own Buy rating and a $26.00 target on October 14. Oric reported a quarterly GAAP net loss of $41.49 million for the period ended June 30, compared with a $36.36 million loss a year earlier.